{
  "created_at": "Sat Oct 23 21:14:22 +0000 2021",
  "id_str": "1452001932000780297",
  "full_text": "Pfizer-BioNTech's Covid-19 booster shot was 95.6% effective in a large study that took place while the Delta variant was prevalent, the companies said https://t.co/OPQ6U3kyqm",
  "display_text_range": [
    0,
    174
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/OPQ6U3kyqm",
        "expanded_url": "https://on.wsj.com/3jrjhdo",
        "display_url": "on.wsj.com/3jrjhdo",
        "indices": [
          151,
          174
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 29,
  "favorite_count": 95,
  "possibly_sensitive": false,
  "original_created_at": "Sat Oct 23 20:00:12 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "ファイザー・バイオンテック社のCovid-19ブースターショットは、デルタ型が流行していた時期に行われた大規模な研究において、95.6%の有効性を示したと両社は発表した。https://t.co/OPQ6U3kyqm"
    },
    {
      "locale": "zh",
      "full_text": "辉瑞-生物技术公司的Covid-19加强针在一项大型研究中的有效率为95.6%，该研究是在Delta变体普遍存在的情况下进行的，这两家公司说https://t.co/OPQ6U3kyqm。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "輝瑞-生物技術公司的Covid-19加強針在一項大型研究中的有效率爲95.6%，該研究是在Delta變體普遍存在的情況下進行的，這兩家公司說https://t.co/OPQ6U3kyqm。"
    }
  ]
}